Bilateral Central Serous Chorioretinopathy After Treatment of COVID-19 Infection

We report a rare case of bilateral central serous chorioretinopathy (CSCR) after COVID-19 management with steroids. The patient was a 49-year-old female who presented with bilateral blurred vision three months after the COVID-19 infection. She had been treated with intravenous Remdesivir and Dexamet...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharifi, Ali, Daneshtalab, Arash, Zand, Amin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Ophthalmology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9038508/
https://www.ncbi.nlm.nih.gov/pubmed/35494916
http://dx.doi.org/10.7759/cureus.23446
Descripción
Sumario:We report a rare case of bilateral central serous chorioretinopathy (CSCR) after COVID-19 management with steroids. The patient was a 49-year-old female who presented with bilateral blurred vision three months after the COVID-19 infection. She had been treated with intravenous Remdesivir and Dexamethasone. After her recovery from the disease, she developed gradual visual impairment in both her eyes. Upon examinations and optical coherence tomography, bilateral CSCR was revealed. She was treated with eplerenone (25 mg/day) and propranolol (20 mg/day), and the symptoms were improved after two months. Post-COVID-19 associated CSCR can occur due to steroids administration. Therefore, patients and physicians should be aware of these possible complications and seek an ophthalmology consultation as early as possible.

Ejemplares similares